Maxim Group upgraded Annovis Bio from Hold to Buy and set a new price target of $25.00

Canaccord Genuity initiated coverage of Annovis Bio with a rating of Buy and set a new price target of $36.00

Maxim Group reiterated coverage of Annovis Bio with a rating of Buy and set a new price target of $150.00 from $45.00 previously

8-K - Annovis Bio, Inc. (0001477845) (Filer)

10-Q - Annovis Bio, Inc. (0001477845) (Filer)

8-K - Annovis Bio, Inc. (0001477845) (Filer)

8-K - Annovis Bio, Inc. (0001477845) (Filer)

8-K - Annovis Bio, Inc. (0001477845) (Filer)

10-Q - Annovis Bio, Inc. (0001477845) (Filer)

8-K - Annovis Bio, Inc. (0001477845) (Filer)

8-K - Annovis Bio, Inc. (0001477845) (Filer)

8-K - Annovis Bio, Inc. (0001477845) (Filer)

8-K - Annovis Bio, Inc. (0001477845) (Filer)

MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that its President and CEO, Maria Maccecchini, Ph.D., has been invited to speak at the National Institute on Aging (NIA) workshop, "Dementia with Lewy Bodies: Filling the Gaps in Translational and Clinical Research." This prestigious workshop, sponsored by the NIA and the National Institute of Neurological Disorders and Stroke (NINDS), will be held on November 12-13, 2024, and accessible

MALVERN, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced financial results for the third quarter ended September 30, 2024, and provided a business update. "The third quarter was marked by important milestones outlining the next steps for buntanetap," said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. "The FDA gave us the green light to initiate confirmatory Phase 3 studies for early AD, and our team has been working hard to begin th

MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson will be responsible for medical, ethical, and scientific quality and rigor in the initiation, conduct, reporting, and successful completion of Annovis' clinical trials. "We are thrilled to welcome Matthew Peterson to our team," said Cheng Fang, Ph.D., Senior Vice President, Research and Development,

LOS ANGELES, Oct. 31, 2024 (GLOBE NEWSWIRE) -- via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast showcases fast-paced interviews with industry experts pioneering pharmaceutical and biotech advancements. The latest episode features Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio (NYSE:ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurode

MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will present two scientific posters at the 17th Clinical Trials on Alzheimer's Disease (CTAD) conference. The event will be held from October 29 to November 1, 2024, in Madrid, Spain. Dr. Maria Maccecchini, President and CEO of Annovis Bio, will present the following posters: Poster LP023 Title: Efficacy of Buntanetap in Early AD and APOE4 Phase 2/3 Alzheimer's Patients. Date: Tuesd

MALVERN, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), announced today the successful outcome of the End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on October 10, 2024. During the meeting, the FDA granted clearance to proceed with pivotal Phase 3 studies, based on the Company's Phase 2/3 clinical data showing symptomatic improvement in early AD patients. Annovis and the FDA have now aligned on a development path for buntanetap towar

NetworkNewsWire Editorial Coverage NEW YORK, Oct. 3, 2024 /PRNewswire/ -- Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and repurposing existing drugs to address unmet medical needs. This strategic approach holds promise for providing hope to millions of patients suffering from historically challenging diseases. Alzheimer's disease (AD) for example, has become a focal point of this innovation, with recent U.S. Food and Drug Administration (FDA) approvals of Leqembi and Kisunla — although these treatments only slow cognitive decline rather than improve cognitive function. New uses for approved glucagon-like pept

NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Annovis Bio Inc. (NYSE:ANVS) announces the availability of a broadcast titled, "Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition." To hear the AudioPressRelease, please visit: The NetworkNewsAudio To view the full editorial, please visit: https://nnw.fm/ZIUid Annovis Bio Inc. is at the forefront of the movement to develop new safe and effective drugs for neurodegenerative diseases, including AD. The company has long pursued the goal to improve the health of nerve cells and, in the process, improve cognition in neurodegenerative disorders. The company's lead drug candidate, buntanetap

NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Annovis Bio Inc. (NYSE:ANVS) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, "Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition," please visit: https://nnw.fm/ZIUid Alzheimer's disease (AD) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have r

NetworkNewsWire Editorial Coverage NEW YORK, Oct. 1, 2024 /PRNewswire/ -- Alzheimer's disease (AD) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received U.S. Food and Drug Administration (FDA) approval. However, while these treatments may slow cognitive decline in AD patients, they do not actually improve cognition, a critical target for the millions suffering from the progressive disease. In addition, GLP-1 (glucagon-like peptide-1) drugs, which were originally developed to manage type 2 diabetes and since have seen significant effectiveness in treating obesity, have also shown potential in the treatment of Alzheimer's. However, th

4 - Annovis Bio, Inc. (0001477845) (Issuer)

4 - Annovis Bio, Inc. (0001477845) (Issuer)

4 - Annovis Bio, Inc. (0001477845) (Issuer)

4 - Annovis Bio, Inc. (0001477845) (Issuer)

4 - Annovis Bio, Inc. (0001477845) (Issuer)

4/A - Annovis Bio, Inc. (0001477845) (Issuer)

4/A - Annovis Bio, Inc. (0001477845) (Issuer)

4/A - Annovis Bio, Inc. (0001477845) (Issuer)

4/A - Annovis Bio, Inc. (0001477845) (Issuer)

4/A - Annovis Bio, Inc. (0001477845) (Issuer)

SC 13G/A - Annovis Bio, Inc. (0001477845) (Subject)

SC 13G - Annovis Bio, Inc. (0001477845) (Subject)

MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson will be responsible for medical, ethical, and scientific quality and rigor in the initiation, conduct, reporting, and successful completion of Annovis' clinical trials. "We are thrilled to welcome Matthew Peterson to our team," said Cheng Fang, Ph.D., Senior Vice President, Research and Development,

BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD) today announced the appointment of Andrew Walsh as VP, Finance.  "We remain steadfast in advancing our lead candidate buntanetap, as we gear up to receive pivotal data from both our Alzheimer's and Parkinson's clinical trials in 2024. The addition of Andrew Walsh to our team marks another step in our growth plans," said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. "Andrew brings 12 years of extensive experience in finance operations, adding a

TheracosBio today announced the appointment of former US Congressman Jim Greenwood to the Board of Directors of its parent company and Jeff McGroarty, MBA, as its Chief Financial Officer. Congressman Greenwood is an established leader in life sciences across business and public policy, and Mr. McGroarty has served as a CFO of public and private life sciences and technology companies. Both newly appointed team members will help shape the commercial strategy for Brenzavvy™ (bexagliflozin), a recently FDA-approved treatment for type 2 diabetes. "Accomplished leaders, Jim and Jeff will be valuable members of our team at this critical time for TheracosBio," said Albert R. Collinson, Ph.D., Pres

BERWYN, Penn., Nov. 8, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced third quarter financial results for the quarter ended September 30, 2022, and reviewed recent accomplishments. Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis, commented: "This quarter, we have made significant advances in the clinical development of buntanetap as we began to dose patients in our Phase 3 trial for early Parkinson's Disease and received FDA author

BERWYN, Pa., Aug. 29, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced the appointment of Henry Hagopian III as Chief Financial Officer, effective immediately.  Mr. Hagopian comes to Annovis with 30 years of finance and accounting experience, including 15 years of increasing responsibility at Organogenesis, a leading publicly-traded regenerative medicine company.  The company has also announced that Jeff McGroarty has stepped away from his role as Chief Financial Officer to pursue other interests.  Mr. McGroarty will assist in an orderly transition of his duties over the ne

Berwyn, Pennsylvania--(Newsfile Corp. - May 4, 2022) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced first quarter financial results for the quarter ended March 31, 2022, and provided a corporate update.Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis, commented, "we have made significant progress advancing buntanetap in Parkinson's disease and Alzheimer's disease this quarter. We received positive feedback from the U.S. Food and Drug Administration (FDA) for two Phase 3 clinical trials with buntanetap in early and late Parkinson's disease. As our clinical trials ad

Company Appoints Eve Damiano, MS, RAC, as Senior Vice President of Regulatory OperationsCompany Promotes Cheng Fang, Ph.D., to Senior Vice President of Research & DevelopmentBerwyn, Pennsylvania--(Newsfile Corp. - January 10, 2022) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the appointment of Eve Damiano, MS, RAC, as its new Senior Vice President of Regulatory Operations, and the promotion of Cheng Fang, Ph.D., to Senior Vice President of Research & Development, as of January 1, 2022."We are all delighted to welcome Ms. Damiano to our diverse team of highly motivated industry expe

Dr. Fang has authored 15 published papers including two on axonal transport and several on protein aggregationBerwyn, Pennsylvania--(Newsfile Corp. - May 18, 2021) - Annovis Bio Inc. (NYSE:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the appointment of Cheng Fang, Ph.D., as its new Vice President of Research."I am excited to welcome Dr. Fang to Annovis Bio. Her knowledge of research in our field, as well as in general, is excellent," commented Maria Maccecchini, Ph.D., CEO of Annovis Bio. "She will be instrumental in furthering our work on the mechanism of action of our drug

Berwyn, Pennsylvania--(Newsfile Corp. - April 15, 2021) - Annovis Bio Inc. (NYSE:ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the appointment of Reid S. McCarthy to its Board of Directors and to the role of Audit Committee chairman, effective April 9, 2021.A specialist in bank, bond, and equity financings, McCarthy retired after serving from 2016 to 2019 as CFO of JJ Haines & Company, Inc., a $400 million revenue distribution company operating internationally. Previously, McCarthy provided CFO consulting services to several life sciences companies, served as CFO of Topaz Pharm

Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), announced today the issuance of a U.S. patent for methods of treating acute traumatic brain injuries (TBI) with its lead drug candidate, buntanetap.In 2016, the Company filed a patent covering the treatment of various nerve insults, including TBI, stroke, and nerve and spinal cord injuries. While these claims were granted in Europe and worldwide, the U.S. Patent and Trademark Office (USPTO) required the claims to be divided into individual patents for each indic

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Annovis Bio (NYSE:ANVS) with a Buy and maintains $30 price target.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Morgan Stanley cut the price target for Microchip Technology Incorporated (NASDAQ:MCHP) from $102 to $100. Morgan Stanley analyst Joseph Moore downgraded the stock from Overweight to Equal-Weight. Microchip Technology shares rose 3.9% to close at $95.98 on Wednesday. See how other analysts view this stock. Truist Securities lifted the price target for Astrana Health, Inc. (NASDAQ:ASTH) from $44 to $50. Truist Securities analyst Jailendra Singh upgraded the stock from Hold to Buy. Astrana Health sha

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Annovis Bio (NYSE:ANVS) with a Buy and raises the price target from $23 to $30.

Shares of SeaStar Medical Holding Corporation (NASDAQ:ICU) fell sharply during Wednesday's session after the company entered into a $10 million registered direct offering of 947,868 shares at $10.55 per share. SeaStar Medical shares dipped 34% to $8.55 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) shares jumped 139% to $2.78 after the company announced results for a Swine Model pilot study for Probudur. Kazia Therapeutics Limited (NASDAQ:KZIA) gained 129% to $0.4325 after the company announced results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of

Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family reasons, effective July 5, 2024. NIO shares dipped 8.5% to $4.4550 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Qualigen Therapeutics, Inc. (NASDAQ:QLGN) jumped 120% to $0.3870 after gaining 6% on Wednesday. Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) rose 70.5% to $4.65 after gaining around 14% on Wednesday. MediWound Ltd. (NASDAQ:MDWD) shares jumped 45.6% to $21.12 after dipping around 7% on Wednesday. Koss Corporation (NASDAQ:KOSS) shares climb